Compare SANA & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SANA | ACHV |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 688.5M | 726.5M |
| IPO Year | 2021 | 2018 |
| Metric | SANA | ACHV |
|---|---|---|
| Price | $2.36 | $6.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $8.43 | ★ $14.15 |
| AVG Volume (30 Days) | ★ 2.9M | 1.3M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.24 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.22 | $2.62 |
| 52 Week High | $5.63 | $8.64 |
| Indicator | SANA | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 32.63 | 37.54 |
| Support Level | $2.22 | $6.22 |
| Resistance Level | $3.41 | $6.64 |
| Average True Range (ATR) | 0.15 | 0.35 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 20.00 | 25.40 |
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.